abrdn US Small Cap Equity A holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
abrdn U.S. Small Cap Equity Fund Class A GSXAX
- NAV / 1-Day Return $44.99 / −0.62 %
- Fund Size $373.4M
- Adjusted Expense Ratio 1.350%
- Net Expense Ratio 1.360%
- Fee Level: Distribution Above Average
- Share Class Type Front Load
- Morningstar Category Small Blend
- Equity Style Box (Funds) Small Growth
- Minimum Initial Investment $1,000
- Investment Status Open
- TTM Yield 0.00%
- Turnover Ratio 48%
Morningstar’s Analysis GSXAX
Will GSXAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 26.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Ligand Pharmaceuticals Inc | 2.89 | 10M | Healthcare |
Q2 Holdings Inc | 2.80 | 10M | Technology |
Kiniksa Pharmaceuticals International PLC Class A | 2.80 | 10M | Healthcare |
Magnolia Oil & Gas Corp Class A | 2.78 | 10M | Energy |
Wintrust Financial Corp | 2.68 | 10M | Financial Services |
ANI Pharmaceuticals Inc | 2.67 | 10M | Healthcare |
WSFS Financial Corp | 2.51 | 9M | Financial Services |
Seacoast Banking Corp of Florida | 2.48 | 9M | Financial Services |
Supernus Pharmaceuticals Inc | 2.48 | 9M | Healthcare |
Ameris Bancorp | 2.39 | 9M | Financial Services |